In the NCCN guideline, the FDA-approved 22C3 IHC assay for PD-L1 utilizes a cutoff of 50% tumor proportion score (TPS) for first-line therapy and 1% TPS for second-line therapy with pembrolizumab in NSCLC [1]. Here, CD274 is linked to neoplasm.